Feasibility and acceptability of GeneXpert MTB/XDR implementation among healthcare workers in three low-middle income African countries
- PMID: 40554504
- PMCID: PMC12186877
- DOI: 10.1371/journal.pone.0326342
Feasibility and acceptability of GeneXpert MTB/XDR implementation among healthcare workers in three low-middle income African countries
Abstract
Background: Xpert MTB/XDR (Xpert-XDR) testing can significantly shorten time to initiating appropriate drug-resistant tuberculosis (DR-TB) treatment, but its introduction may impact laboratory workflow, especially in laboratories not currently performing drug susceptibility testing. This study evaluated the feasibility and acceptability of implementing the Xpert-XDR for rapid triage and selection of all-oral regimens for DR-TB.
Method: This was a multi-country, multi-site qualitative study conducted between July and November 2023, as part of the larger TriAD (Triage test for All oral DR TB drugs) study implemented in South Africa, Ethiopia, and Nigeria. We conducted semi-structured in-depth interviews with clinicians, nurses and laboratory staff at each study site until thematic saturation was achieved. Additionally, we interviewed policy makers (n = 9) and people with TB (PWTB) (n = 11), to provide additional insight on the implementation of this new diagnostic assay.
Results: Healthcare workers (n = 61) found the new workflow feasible and acceptable. It was the increased speed in which PWTB would receive a correct diagnosis and appropriate treatment that provided the biggest benefit to moving to Xpert-XDR for healthcare workers and PWTB. Laboratory staff mentioned that Xpert-XDR had expedited and simplified the laboratory workflows. Role-appropriate and ongoing training is a key factor in effective implementation as described by policy makers and healthcare workers alike. Barriers impacting the ability to perform Xpert-XDR included unstable power supply, internet, and temperature control. Additionally, the Xpert MTB/Rif Ultra test has higher sensitivity for the detection of TB than the Xpert-XDR test, leading to discordant test results.
Conclusion: This study showed that implementation of Xpert-XDR in health facilities is both feasible and acceptable by all types of healthcare workers. Some barriers with Xpert-XDR are not exclusive to this particular diagnostic tool but are important to address when policy makers are deciding which tools to implement.
Copyright: © 2025 Keller et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Conflict of interest statement
The authors have declared that no competing interests exist.
Similar articles
-
Rapid molecular tests for tuberculosis and tuberculosis drug resistance: a qualitative evidence synthesis of recipient and provider views.Cochrane Database Syst Rev. 2022 Apr 26;4(4):CD014877. doi: 10.1002/14651858.CD014877.pub2. Cochrane Database Syst Rev. 2022. PMID: 35470432 Free PMC article.
-
Triage test for all-oral drug-resistant tuberculosis (DR-TB) regimen: a phase IV study to assess effectiveness, feasibility, acceptability and cost-effectiveness of the Xpert MTB/XDR assay for rapid triage and treatment of DR-TB.BMJ Open. 2024 Nov 27;14(11):e084722. doi: 10.1136/bmjopen-2024-084722. BMJ Open. 2024. PMID: 39609025 Free PMC article.
-
Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin.Cochrane Database Syst Rev. 2022 May 18;5(5):CD014841. doi: 10.1002/14651858.CD014841.pub2. Cochrane Database Syst Rev. 2022. PMID: 35583175 Free PMC article.
-
Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance.Cochrane Database Syst Rev. 2018 Aug 27;8(8):CD012768. doi: 10.1002/14651858.CD012768.pub2. Cochrane Database Syst Rev. 2018. Update in: Cochrane Database Syst Rev. 2021 Jan 15;1:CD012768. doi: 10.1002/14651858.CD012768.pub3. PMID: 30148542 Free PMC article. Updated.
-
Xpert MTB/RIF Ultra assay for tuberculosis disease and rifampicin resistance in children.Cochrane Database Syst Rev. 2022 Sep 6;9(9):CD013359. doi: 10.1002/14651858.CD013359.pub3. Cochrane Database Syst Rev. 2022. PMID: 36065889 Free PMC article.
References
-
- Global tuberculosis report 2024. Geneva: World Health Organization; 2024.
-
- Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respir Med. 2017;5(4):291–360. doi: 10.1016/S2213-2600(17)30079-6 - DOI - PubMed
-
- WHO consolidated guidelines on tuberculosis. Module 3: diagnosis – rapid diagnostics for tuberculosis detection. 3rd ed. Geneva: World Health Organization. 2024. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources